Combination Therapy Extends Survival in Patients with Severe Heart Disease
A groundbreaking study shows that combining valve replacement with targeted drug therapy significantly improves survival in patients with severe heart conditions, including aortic stenosis and cardiac amyloidosis.
Recent research conducted by an international consortium led by MedUni Vienna and University College London has revealed promising advancements in treating severe heart conditions, particularly in patients suffering from both aortic stenosis and cardiac amyloidosis. Traditionally, treatments focused solely on mechanical interventions such as valve replacement, leaving the amyloid deposits in the heart muscle often untreated. However, the new study demonstrates that a combined approach—integrating aortic valve replacement with targeted drug therapy for amyloidosis—significantly improves patient survival rates.
The study analyzed data from 226 patients across ten countries, all diagnosed with both aortic stenosis and cardiac amyloidosis. Aortic stenosis involves the narrowing of the heart valve, obstructing blood flow from the heart's left ventricle into the circulation. Cardiac amyloidosis occurs when misfolded proteins deposit in the heart tissue, impairing its function. Both conditions predominantly affect older adults and frequently coexist.
Importantly, the research shows that patients receiving both valve replacement and tafamidis, a drug used to treat amyloidosis, had notably better survival outcomes. In fact, those who underwent both treatments displayed long-term survival rates similar to patients with aortic stenosis alone without amyloidosis. This underscores the importance of comprehensive treatment strategies.
The findings advocate for routine screening for amyloidosis in patients with severe aortic stenosis. Recognizing the co-occurrence enables healthcare providers to administer targeted therapies that can prolong life and improve quality of life. Early detection and combined treatment are crucial in managing these complex, age-related cardiac diseases.
Overall, this research highlights the potential to change clinical practice by emphasizing the importance of diagnosing and treating both conditions concurrently, paving the way for better patient outcomes in severe heart disease cases.
Source: https://medicalxpress.com/news/2025-06-combination-therapy-prolong-life-severe.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Potential Cuts to Children's Health Services Under Medicaid Spending Proposals
Congress discusses potential Medicaid spending cuts that could impact essential health services for millions of children, risking reduced access to care and vital programs like vaccinations and school-based health services.
Innovative Blood Test Could Revolutionize Bone Marrow Sampling for Leukemia Detection
A new blood test developed by researchers at the Weizmann Institute of Science offers a less invasive way to detect leukemia and blood disorders by analyzing circulating blood stem cells, potentially replacing traditional bone marrow biopsies.
New Experimental Drug Targets Body's Circadian Clock to Combat Glioblastoma
A groundbreaking compound, SHP1705, targets the circadian clock proteins hijacked by glioblastoma stem cells, offering hope for improved treatments of this aggressive brain cancer.